Precision BioSciences, Inc. (LS:A400AS) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$125M · US$7.75 a share · TD Cowen +1 Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead) Buyers: First Light Asset Management; MPM BioImpact; Bleichroeder LP; Lynx1 Capital Management; Readout Capital; Aberdeen Investments; Driehaus Capital Management Use of proceeds: Continued research and development of PBGENE-HBV and PBGENE-DMD, working capital and general corporate purposes | Nov 5, 2026 |
| Strategic investment of common stock Announced: US$2.25M · US$11.17 a share Buyers: TG Therapeutics, Inc. ($2.25 million for 201,504 shares of common stock at $11.17 per share) Use of proceeds: Supports cash runway through 2028 and focus on in vivo gene editing pipeline | Mar 2, 2026 |
| Public offering of common stock, pre-funded warrants and warrants Announced: about US$75M · US$6.14 a share · ½ warrant at US$7.25 for 60 months · Guggenheim Securities Dealers: Guggenheim Securities (lead) Buyers: Aberdeen Investments; Bleichroeder LP; Driehaus Capital Management; Empery Asset Management LP; Lynx1 Capital Management; Octagon Capital; Readout Capital; Sphera Funds Management; Stonepine Capital Management Use of proceeds: Ongoing and planned research and development, working capital and general corporate purposes | Nov 10, 2025 |